2024-10-25 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global pharmaceutical company that develops, manufactures, and markets a wide range of biopharmaceutical products.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return (ABBV):** 146.5%
* **Cumulative Return (VOO):** 135.48%
* **Difference:** 11.02%
* **Relative Divergence:** 52.99% (This indicates that ABBV's performance is in the top 52.99% of its historical range compared to VOO) 

**2. Recent Price Movement:**

* **Closing Price:** $189.65
* **5-Day Moving Average:** $187.9
* **20-Day Moving Average:** $192.57
* **60-Day Moving Average:** $193.22

**3. Technical Indicators:**

* **RSI:** 37.57 (Neutral: Indicates the stock is neither overbought nor oversold.)
* **PPO:** -0.33 (Negative: Suggests a potential downtrend, but a small negative value indicates a weak signal.)
* **Delta_Previous_Relative_Divergence:** -4.46 (Negative: Indicates a short-term downward trend.)
* **Expected Return:** 3.06% (This is the projected long-term (2+ years) excess return over the S&P 500 assuming consistent investment.)

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

AbbVie's most recent earnings report (July 25, 2024) exceeded analysts' expectations, with EPS of $2.65 against a forecast of $2.57. This indicates that the company is performing well and exceeding expectations.

**5. News and Recent Issues:**

* **Recent Earnings Release:** AbbVie's recent earnings call discussed strong performance in its Immunology and Oncology segments. The company also highlighted its commitment to pipeline development and innovation.
* **Recent Market Outlook:** While the overall market sentiment for AbbVie is positive, some analysts are cautious about the future of its flagship drug Humira, as it faces biosimilar competition. However, the company's diverse portfolio and commitment to research and development are considered positive factors.
* **Analyst Opinions and Performance Highlights:** According to Finbold, AbbVie is currently rated as a "Strong Buy" by most analysts. The stock is viewed as a value pick with potential for growth driven by its strong pipeline and consistent earnings performance.

**6. Overall Analysis:**

AbbVie (ABBV) is currently exhibiting strong financial performance, exceeding earnings expectations in the most recent quarter. While its stock is currently trading slightly below its moving averages, its performance has outpaced the S&P 500 over a longer period. Its technical indicators show some short-term weakness, but long-term projections are positive with a projected excess return of 3.06% over the S&P 500. Overall, despite concerns about Humira's future, ABBV's diversified portfolio, commitment to innovation, and strong earnings make it a promising investment opportunity.

**7. Key Takeaways:**

* **Strong Financial Performance:** AbbVie consistently exceeds earnings expectations, highlighting its robust business model.
* **Long-Term Growth Potential:** The company's diverse portfolio and commitment to research and development ensure continued growth in the long term.
* **Attractive Valuation:** Despite some recent market concerns, ABBV's stock remains attractively valued compared to its competitors.
* **Potential Risks:** The introduction of biosimilars for Humira poses a risk to future growth. However, AbbVie is actively mitigating this risk through its robust pipeline and diversification efforts.

**Disclaimer:** This information is for educational purposes only and should not be considered as investment advice. 
